# Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

> **NCT02228369** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 108 (actual)

## Conditions studied

- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD3759
- **DRUG:** AZD9291

## Key facts

- **NCT ID:** NCT02228369
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-05
- **Primary completion:** 2017-08-19
- **Final completion:** 2020-10-28
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228369, "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02228369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*